AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06084533
Drug: [11C]-CS1P1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
Trial: NCT05521152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06266611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
Trial: NCT04849533
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: belatacept with chronic steroids is approved regimen for prevention of rejection
Trial: NCT06497504
Drug: Bepirovirsen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bepirovirsen will be administered.
Trial: NCT06497504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered.
Trial: NCT05278494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO
Trial: NCT06319872
Drug: Oral disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg/day
Trial: NCT05292976
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One actuation each from two different placebo Reference inhalation aerosols and one actuation each from two different placebo Test inhalation aerosols.
Trial: NCT06274151
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury
Trial: NCT06274151
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
Trial: NCT05699876
Drug: Melatonin 6 MG
RxNorm normalized name: melatonin 6 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: melatonin will be administered orally preoperatively as premedication
Trial: NCT05543681
Drug: IGC-AD1-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-sterile solution for oral administration similar in color and texture to the Active.
Trial: NCT05050500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients meeting the inclusion criteria will be randomized to receive a placebo tablet every 24 hours for 6 months.
Trial: NCT04864145
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-neprilysin inhibition (ARNI), diuretics, dihydropyridine calcium channel blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs) or beta blockers.
Trial: NCT04895488
Drug: Usual Antipsychotic Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second treatment phase. Usual antipsychotic treatment for 26 weeks: Allows for whatever medication, routine support, or referral to other services was felt appropriate by the clinician.
Trial: NCT05619770
Drug: 101-PGC-005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus Injection containing 30mg of 101-PGC-005 will administered intravenously once daily for 3 consecutive days
Trial: NCT01194193
Drug: AZD8055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
Trial: NCT05576428
Drug: NAC with diet and exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAC with diet and exercise in patients of NAFLD
Trial: NCT04675086
Drug: Antiviral Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization
Trial: NCT04926506
Drug: Xiyanping injection
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
Trial: NCT06384235
Drug: LTC004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTC004,45μg/kg,IV,Day 1,Q3W;
Trial: NCT06396013
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment: According to the recommendations of the Guidelines, all participant took the traditional Chinese medicine decoction Huoxue Sanyu Decoction orally. 2 times/day for 12 weeks.~Acute administration: When the participant has unbearable itching, the doctor can give loratadine tablet 10mg orally once a night, and record the dosage and frequency of use.
Trial: NCT05821075
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prednisolone 60mg tablet once daily for 5 days then tapering dose
Trial: NCT04559646
Drug: Haemostatic solution Haemoblock application
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemostatic solution Haemoblock will be used after pocket formation during pacemaker implantation.
Trial: NCT05112159
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets to IPG1094 50mg and 100mg
Trial: NCT06080165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT05807971
Drug: ATH-063
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 and 50 mg Capsules, anticipated dose range to be from 25 to 250 mg.
Trial: NCT05807971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical capsule to the drug without the active ingredient.
Trial: NCT06359197
Drug: Caffeine Pill
RxNorm normalized name: caffeine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants would take two Wake-Ups 200mg Caffeine tablets to meet the target dose of 400mg of caffeine. These are a registered natural health product with Health Canada (NPN 80003474). They are developed by Adrem Brands, which was established in 1951. Quality control testing is performed at a third-party independent lab, Nucro-Technics, which is audited by Health Canada and the US FDA. This ensures that the caffeine tablets comply with Health Canada standards. The tablets contain caffeine anhydrous-a processed, dehydrated form of caffeine-which allows for a standard dose per tablet. The tablets are sugar-free, which reduces the confounding effect of sugar on our results; thus, the investigators can be more confident that the obtained results are reflective of the association between caffeine and the CVD-related protein biomarkers.
Trial: NCT06359197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants would take two placebo pills to match the dosage of the intervention group. The investigators will use empty vegetable capsules from Health Bloom as the placebo for the control group. These capsules contain no contaminants or additives and are free from the common allergens. They are sugar-free-unlike most placebo pills, which reduces the confounding effect of sugar on our results. They are developed by Health Bloom, which is a Canadian company established in 2015. These capsules undergo testing at various stages of production to ensure purity and quality control. Each ingredient is tested prior to formulation, and the final capsules are subjected to thorough testing post-development. The capsules are white, and similar in appearance to the caffeine pill given to participants in the intervention group.
Trial: NCT02358018
Drug: 68Ga-DOTATOC PET/CT Scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately \~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
Trial: NCT06196697
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive AK104 and AK112 in combination with XELOX(oxaliplatin and capecitabine)
Trial: NCT04235322
Drug: 2LHERP®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT04235322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Trial: NCT05338866
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For patients with AJCC stage II and III and age \< 72 years old, Capox ×6→capecitabine×2.~Detailed usage: Oxaliplatin 130mg/m2 (reduced to 100mg/m2 during concurrent chemoradiotherapy), intravenous administration, d1. Capecitabine 1000mg / m2, twice a day, d1-14. Repeated every 3 weeks.~For patients aged ≥ 72 years, or the competent physician judges that the patients cannot tolerate dual drug combined chemotherapy, capecitabine ×8 courses.~For patients with AJCC stage I, capecitabine ×4 courses.
Trial: NCT00013923
Drug: Nutritional Supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00282061
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06207760
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline (200 mg/day) for 8 weeks with a single daily administration (2 hard capsules of 100 mg)
Trial: NCT04987463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
Trial: NCT04987463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
Trial: NCT06155032
Drug: Best medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
Trial: NCT04638803
Drug: PRX-P4-003, (-)-FCF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sequential study
Trial: NCT05398705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1\~5: placebo+SMT~SMT:standardized medical treatment according to Scheme for Diagnosis and Treatment of 2019 Novel Coronavirus Pneumonia (The 9th Trial Edition) from health commission of China, including bed rest, adequate energy and nutrition, pay attention to water and electrolyte balance to maintain a stable internal environment, closely monitor, antiviral drug and Chinese medicine treatment, etc.
Trial: NCT06345014
Drug: OM-89 [Uro-Vaxom® Capsule]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of the investigational product (OM-89 \[Uro-Vaxom® Capsule\] or the placebo) once a day
Trial: NCT06345014
Drug: OM-89 Placebo [Uro-Vaxom® Capsule Placebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of the investigational product(Placebo of Uro-Vaxom® Capsule)
Trial: NCT04842552
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05096598
Drug: ZP8396
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 single dose of ZP8396 given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm). Dose level will depend on the cohort.
Trial: NCT05096598
Drug: Placebo (ZP8396)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 1 single dose of placebo given subcutaneously (s.c., under the skin) or intravenously (i.v., in a vein of the arm).
Trial: NCT06174545
Drug: Pigment Solution Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adjuvant therapy for melasma that contains of combination formula consisting of morning cream - containing kojic acid, Vitamin E, Vitamin A and AquaxylTM complex; night cream - contains kojic acid, glycolic acid and AquaxylTM complex, scrub granules; and cleaning fluid containing vegetable oil and lactic acid.
Trial: NCT05750628
Drug: INE963
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral INE963
Trial: NCT05750628
Drug: KLU156
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral sachet KLU156 (KAF156 + lumefantrine)
Trial: NCT04542434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets 3 times daily for 14 days
Trial: NCT05732077
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A bolus dose of 50μg/kg dopamine via renal artery to induce hyperemic status
Trial: NCT05979207
Drug: MMV367
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT05180890
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion.
Trial: NCT04876131
Drug: Gentamicin - single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)
Trial: NCT04876131
Drug: Gentamicin - three days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive three days of this IV antibiotic (gentamicin).~Gentamicin dosing: Children ≤10 years old: 7.5 mg/kg (maximum dose 320 mg) Children \>10 years old: 6-7 mg/kg (maximum dose 560 mg)
Trial: NCT04876131
Drug: Cefalexin - post single dose of IV antibiotics for the remaining two days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotic will be as per local guidelines. i.e. Cefalexin 25mg/kg (maximum dosage 500mg) 4 times a day or 33mg/kg (maximum dosage 500mg) 3 times a day
Trial: NCT05192395
Drug: DWJ1525
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWJ1525
Trial: NCT05192395
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWP16001
Trial: NCT05192395
Drug: DWC202101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWC202101
Trial: NCT04992624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug will be taken similarly to the THC and CBD and be matched to keep the trial blinded.~In the event that 2.5 mg capsules of dronabinal capsules become unavailable, an equivalent product will be issued to participants and the comparator and placebo arms will be correspondingly adjusted to preserve blinding. If a participant's dose is not well-tolerated, the participant may initiate dose reductions with the study team.~Participants will be instructed to eat a meal or snack greater than one hour after taking study drug.
Trial: NCT04801043
Drug: XNW4107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XNW4107 250mg IV over 60 minutes as a single dose
Trial: NCT04801043
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to XNW4107 containing the same inactive ingredients IV over 60 minutes as a single dose~Matching placebo to Imipenem/Cilastatin 0.9% sodium chloride IV over 60 minutes as a single dose
Trial: NCT05805605
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as a 2 hour IV infusion on day -6, +3, and +4.
Trial: NCT04735796
Drug: Drug：LM-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional '3+3' escalation design will be used. Dose escalation consists of five ascending dose levels of LM-102 (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg and 40 mg/kg). All subjects will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-102 as a 2 h (120±10 min) intravenous (IV) infusion until the disease progression, intolerance, subject discontinuation/informed consent withdrawal, or at the discretion of the investigator in consultation with sponsor, at most till by one year.
Trial: NCT06180083
Drug: 'DYMISTA' NASAL SPRAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose \[four sprays (two sprays in each nostril)\] of 'DYMISTA' (AZELASTINE HYDROCHLORIDE/ FLUTICASONE PROPIONATE) NASAL SPRAY 137 Microgram/50 Microgram
Trial: NCT06730932
Drug: JS004（BTLA monoclonal antibody，intravenously）,Toripalimab（ anti-PD-1specific antibody，intravenously)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection 200mg via IV infusion once every 3 weeks~Toripalimab 240mg via IV infusion once every 3 weeks~JS004 will be administered in combination with toripalimab until disease progression or intolerable toxicity or up to 2 years of treatment or other reasons specified in the protocol
Trial: NCT05318833
Drug: HRS7415
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: HRS7415
Trial: NCT04968522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is Maize Starch and Pregelatinised Maize Starch. The placebo will be encapsulated using the same capsule that is opaque so that participants cannot distinguish the two visually. Where the active mediation amount is small for the capsule, there will be additional Starcke 1500 (Maize Starch and Pregelatinised Maize Starch) added to fill the capsule so that the active drug and capsule also weigh approximately the same. The dose of placebo will be matched to the participants currently prescribed stimulant medication.
Trial: NCT05981014
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Trial: NCT05981014
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Trial: NCT05981014
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Trial: NCT06188676
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclofosfamida
Trial: NCT06188676
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin
Trial: NCT06188676
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolonum
Trial: NCT05483465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually identical pill to NR, daily per os for 8 weeks
Trial: NCT04611776
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously during the induction phase and the maintenance phase.
Trial: NCT04651166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mL saline or lactated ringers
Trial: NCT05202015
Drug: MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI of the liver accoring to our institutional daily routine protocol
Trial: NCT06006598
Drug: Placebo matching BI 1584862
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 1584862
Trial: NCT05683951
Drug: DWKH-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of DWKH-R three times daily
Trial: NCT05683951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Placebo three times daily
Trial: NCT04640376
Drug: Paracetamol Uniflash 125mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oromucosal solution 1.25 mL for buccal use